These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8652942)

  • 1. Positive inotropic agents: a double-edged sword for chronic heart failure.
    Asanoi H; Inoue H
    Intern Med; 1996 Jan; 35(1):63-4. PubMed ID: 8652942
    [No Abstract]   [Full Text] [Related]  

  • 2. [Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Oct; 36(10):1125-31. PubMed ID: 3247528
    [No Abstract]   [Full Text] [Related]  

  • 3. Do levosimendan have an adverse effect on platelet function?
    Kaptan K; Beyan C; Ifran A
    Int J Cardiol; 2010 Oct; 144(3):414-5. PubMed ID: 19327852
    [No Abstract]   [Full Text] [Related]  

  • 4. ST-segment elevation during levosimendan infusion.
    Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 6. Vesnarinone for heart failure.
    Neely D
    N Engl J Med; 1994 Jan; 330(1):65. PubMed ID: 8259152
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe heart failure: balancing length and quality of life.
    Harv Heart Lett; 1999 Jun; 9(10):1-2. PubMed ID: 10233785
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [LEVOSIMENDAN--THE FIRST 10 YEARS IN CLINICAL PRACTICE].
    Rybka MM; Lobacheva GV
    Anesteziol Reanimatol; 2015; 60(5):80-4. PubMed ID: 26852586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotropic therapy for heart failure.
    Stevenson LW
    N Engl J Med; 1998 Dec; 339(25):1848-50. PubMed ID: 9854124
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.
    Sasayama S; Asanoi H; Kihara Y; Yokawa S; Terada Y; Yoshida S; Ejiri M; Horikoshi I
    Heart Vessels; 1994; 9(3):113-20. PubMed ID: 8056717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
    LeJemtel TH
    Curr Cardiol Rep; 1999 May; 1(1):31. PubMed ID: 10980817
    [No Abstract]   [Full Text] [Related]  

  • 13. Inotropic agents in advanced heart failure: repetita iuvant?
    De Luca L
    Int J Cardiol; 2014 Sep; 176(1):6-7. PubMed ID: 25065330
    [No Abstract]   [Full Text] [Related]  

  • 14. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
    Cohn JN; Goldstein SO; Greenberg BH; Lorell BH; Bourge RC; Jaski BE; Gottlieb SO; McGrew F; DeMets DL; White BG
    N Engl J Med; 1998 Dec; 339(25):1810-6. PubMed ID: 9854116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses.
    Walter M; Liebens I; Goethals H; Renard M; Dresse A; Bernard R
    Br J Clin Pharmacol; 1988 Mar; 25(3):323-9. PubMed ID: 3282531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Levosimendan. Clinical indications of a new vasoactive substance].
    Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
    Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on digoxin and other oral positive inotropic agents for chronic heart failure.
    Reddy S; Benatar D; Gheorghiade M
    Curr Opin Cardiol; 1997 May; 12(3):233-41. PubMed ID: 9243080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives.
    Zafrir B; Amir O
    Isr Med Assoc J; 2012 Mar; 14(3):184-9. PubMed ID: 22675861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?
    McLachlan CS; Mossop P
    Eur J Heart Fail; 2006 Mar; 8(2):216-7; author reply 218. PubMed ID: 16488367
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.